Inactive Instrument
Guided Therapeutics Inc Share Price OTC Bulletin Board
Stocks
US40171F2048
Advanced Medical Equipment & Technology
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 15/07 | Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation | CI |
| 16/06 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| Market Cap | 2.51Cr 2.2Cr 2.05Cr 1.88Cr 3.53Cr 241.71Cr 3.59Cr 24Cr 9.51Cr 118.83Cr 9.42Cr 9.22Cr 410.87Cr | P/E 2024 |
-3x | P/E 2025 | -12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.8Cr 2.46Cr 2.29Cr 2.1Cr 3.94Cr 269.41Cr 4Cr 27Cr 11Cr 132.45Cr 11Cr 10Cr 457.95Cr | EV / Sales 2024 |
1,649x | EV / Sales 2025 | 64.4x |
| Free-Float |
63.48% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Faupel
CEO | Chief Executive Officer | 70 | 06/03/2023 |
| Chief Tech/Sci/R&D Officer | 70 | 02/12/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Faupel
BRD | Director/Board Member | 70 | 01/12/2016 |
John Imhoff
BRD | Director/Board Member | 76 | 10/04/2006 |
Michael James
CHM | Chairman | 67 | 01/10/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.74% | +6.96% | +19.90% | -0.34% | 21TCr | ||
| -0.10% | -5.67% | -5.19% | -25.47% | 14TCr | ||
| +2.04% | -1.95% | -30.69% | +4.67% | 12TCr | ||
| +1.62% | +0.80% | -58.21% | -14.93% | 6.48TCr | ||
| -0.94% | -2.58% | +10.18% | -8.63% | 4.83TCr | ||
| +3.03% | -0.17% | -26.81% | -31.58% | 4.31TCr | ||
| -0.65% | +5.57% | +15.31% | +8.66% | 3.95TCr | ||
| -2.09% | +1.47% | +25.44% | +30.47% | 3.75TCr | ||
| -1.42% | +4.20% | +80.68% | +3.41% | 2.98TCr | ||
| Average | +0.06% | -3.37% | +3.40% | -3.75% | 8.09TCr | |
| Weighted average by Cap. | +0.17% | -4.90% | -0.74% | -5.67% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 7T 6.15T 5.72T 5.25T 9.86T 7L 10.01T 67.89T 26.53T 3L 26.28T 25.71T 11.46L | 8L 7L 6L 6L 10.8L 7.39Cr 10.97L 74.39L 29.06L 3.63Cr 28.79L 28.17L 13Cr |
| Net income | -24.17L -21.23L -19.74L -18.12L -34.04L -23Cr -34.56L -2.34Cr -91.59L -11Cr -90.73L -88.78L -40Cr | -31.96L -28.07L -26.1L -23.95L -45.01L -31Cr -45.7L -3.1Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr |
| Net Debt | 17.71L 15.55L 14.47L 13.27L 24.94L 17Cr 25.33L 1.72Cr 67.11L 8.38Cr 66.48L 65.05L 29Cr | 28.76L 25.26L 23.49L 21.56L 40.5L 28Cr 41.13L 2.79Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 47Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















